{"id":33015,"date":"2020-08-11T12:02:10","date_gmt":"2020-08-11T11:02:10","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33015"},"modified":"2021-03-18T10:53:48","modified_gmt":"2021-03-18T10:53:48","slug":"biobanking-2019-speakers","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/","title":{"rendered":"Biobanking 2019 Speakers"},"content":{"rendered":"
\n

\n\tOur
Speakers (A-Z)
\n\t<\/h2>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33142″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/ali-ismail\/ali-ismail-_s-birka_biotech_pharma_summit_biobanking_2018_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"1514223879","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ali-Ismail-_s-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAli Ismail\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Founder at Birka Biostorage<\/h5>\n

\n\t\t\t\n\tRisk management in Biorepositories\n\t\t\t<\/a>\n\t<\/h3>\n\t

Ismail started the company in 2010 in Lund, Southern Sweden. His company, Birka BioStorage, offers safe storage and transportation of biological samples and other sensitive goods. Birka\u00b4s site in Lund is the first certified repository in Scandinavia. The premises are the first cGMP & GDP qualified storage facility in Scandinavia for the banking of biological and pharmaceutical samples.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alissa_Resch_Coriell_Biotech_Pharma_Summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alissa_Resch_Coriell_Biotech_Pharma_Summit_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alissa_Resch_Coriell_Biotech_Pharma_Summit_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alissa_Resch_Coriell_Biotech_Pharma_Summit_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alissa_Resch_Coriell_Biotech_Pharma_Summit_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alissa_Resch_Coriell_Biotech_Pharma_Summit_2-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alissa_Resch_Coriell_Biotech_Pharma_Summit_2-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33032″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/alissa-m-resch\/alissa_resch_coriell_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alissa_Resch_Coriell_Biotech_Pharma_Summit_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Alissa_Resch_Coriell_Biotech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alissa_Resch_Coriell_Biotech_Pharma_Summit_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Alissa_Resch_Coriell_Biotech_Pharma_Summit_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAlissa M. Resch\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chief Scientific Officer at Coriell Institute for Medical Research<\/h5>\n

\n\t\t\t\n\tThe Evolving Role of Biobanks: Developing Metrics to Identify Future Needs\n\t\t\t<\/a>\n\t<\/h3>\n\t

As head of scientific operations at the Coriell Institute for Medicial Research, Dr. Alissa M. Resch oversees the scientific functions of the institute, including management of the contracts & grants portfolio and oversight of the research and project management teams. Prior to her role as Chief Scientific Officer, Alissa served as Director of Biobanking Operations.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33117″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/caoimhe-vallely-gilroy\/caoimhe_vallely-gilroy_merck_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Caoimhe_Vallely-Gilroy_Merck_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tCaoimhe Vallely-Gilroy\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director, Head of Clinical Trials Biosample Management, Merck KGaA<\/h5>\n

\n\t\t\t\n\tHow quality biobanking starts during the clinical trial\n\t\t\t<\/a>\n\t<\/h3>\n\t

Caoimhe is currently the Global Head of Clinical Trial Biosample Management at Merck KGaA, leading a team of biosample operational experts in the feasibility and execution of biosampling strategy in clinical trials, across all trial phases and indications.<\/p>\n\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33020″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/catherine_larue_ibbl_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5.6","credit":"Sandy Keipes – Atelier Photographique","camera":"Canon EOS 5D Mark II","caption":"","created_timestamp":"1373559143","copyright":"u00a9 Sandy Keipes","focal_length":"65","iso":"400","shutter_speed":"0.0125","title":"","orientation":"1"}” data-image-title=”Catherine_Larue_IBBL_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tCatherine Larue\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CEO at IBBL<\/h5>\n

\n\t\t\t\n\tHow research infrastructures can efficiently contribute to translational\/personalised medicine?\n\t\t\t<\/a>\n\t<\/h3>\n\t

After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides. She then joined Sanofi Diagnostics Pasteur, at Minneapolis MN (USA) for 3 years where she was responsible for Assay Development in the immunodiagnostic area.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jan-Eric_Litton_Karolinska_Institutet_Biotech_Pharma_Summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jan-Eric_Litton_Karolinska_Institutet_Biotech_Pharma_Summit_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jan-Eric_Litton_Karolinska_Institutet_Biotech_Pharma_Summit_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jan-Eric_Litton_Karolinska_Institutet_Biotech_Pharma_Summit_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jan-Eric_Litton_Karolinska_Institutet_Biotech_Pharma_Summit_2-630×940.png 630w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33067″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/jan-eric-litton\/jan-eric_litton_karolinska_institutet_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jan-Eric_Litton_Karolinska_Institutet_Biotech_Pharma_Summit_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Jan-Eric_Litton_Karolinska_Institutet_Biotech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jan-Eric_Litton_Karolinska_Institutet_Biotech_Pharma_Summit_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jan-Eric_Litton_Karolinska_Institutet_Biotech_Pharma_Summit_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJan-Eric Litton\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior professor at the Karolinska Institutet<\/h5>\n

\n\t\t\t\n\tReproducibility and Reliability of Biobank Data\n\t\t\t<\/a>\n\t<\/h3>\n\t

Jan-Eric Littonis a Senior professor at the Karolinska Institutet, Stockholm, Sweden.  He was appointed BBMRI-ERIC\u2019s first Director General on 22 January 2014 \u2013 1 August 2017, building up one of the largest infrastructure for Health in Europe. Litton is renowned for his expertise in biobanking and leadership in large-scale projects. He was also heading the development of e-epidemiology by using Internet, cell-phones, digital paper and digital TV for collecting epidemiology data.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33050″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/jens-k-habermann\/jens_habermann_esbb_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"8","credit":"","camera":"Canon EOS 60D","caption":"","created_timestamp":"1439462938","copyright":"","focal_length":"85","iso":"125","shutter_speed":"0.00625","title":"","orientation":"1"}” data-image-title=”Jens_Habermann_ESBB_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJens K. Habermann\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
President of ESBB (European, Middle Eastern and African Society for Biopreservation and Biobanking)<\/h5>\n

\n\t\t\t\n\tHow clinical biobanks and strategic partnerships can support precision medicine: a Lu\u0308beck and ESBB perspective\n\t\t\t<\/a>\n\t<\/h3>\n\t

Professor Jens K. Habermann, m.d., Ph.D., is director of ICB-L (Interdisciplinary Center for Biobanking-L\u00fcbeck) and scientific director of UCCL (University Cancer Center L\u00fcbeck) at the University of L\u00fcbeck and University Clinic Schleswig-Holstein. He obtained his Ph.D. at the Karolinska Institutet (Stockholm, Sweden) and postdoc training at the NCI, NIH (Bethesda, USA).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33094″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/jordan-moore\/jordan_moore_fluidigm_biobank_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.2","credit":"","camera":"iPhone 6s","caption":"","created_timestamp":"1499443966","copyright":"","focal_length":"4.15","iso":"200","shutter_speed":"0.05","title":"","orientation":"1"}” data-image-title=”Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jordan_Moore_Fluidigm_Biobank_Biotech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJordan Moore\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior Field Applications Specialist at Fluidigm<\/h5>\n

\n\t\t\t\n\tConfidently manage sample identity\n\t\t\t<\/a>\n\t<\/h3>\n\t

Jordan Moore is a Senior Field Applications Specialist (FAS) at Fluidigm, helping to ensure that customer projects exceed expectations. Supporting the microfluidics portfolio, he promotes Fluidigm\u2019s continued success in Europe and has supported its ever-expanding genomics portfolio.  Jordan is now a dual Franco-American national and is based out of Lyon, France.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33074″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/karine-sargsyan\/karine-sargsyan-2-biobank-graz_biotech_pharma_summit_biobanking_2018_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"1514381703","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Karine-SargSyan-2-Biobank-Graz_BioTech_Pharma_Summit_Biobanking_2018_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tKarine Sargsyan\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chief Operating Officer at Biobank Graz<\/h5>\n

\n\t\t\t\n\tBiobank Graz: Holistic approach to maintain sample quality\n\t\t\t<\/a>\n\t<\/h3>\n\t

Karine Sargsyan, MD, pediatrician and psychologist, is a native Armenian.<\/p>\n

She joined the Medical University Graz, Austria (MUG) in 2005 within the scope of an international cooperation project after several years in Children\u2019s Republican Hospital in Yerevan, Armenia where she led the Metabolism, Nutrition and Medical Dietetics department.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33105″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/marybeth-joshi\/marybeth-joshi_2-duke-university_biotech_pharma_summit_biobanking_2019_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"1514381703","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marybeth-Joshi_2-Duke-University_BioTech_Pharma_Summit_Biobanking_2019_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMarybeth Joshi\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director, Biobank & Translational Research Core at Duke University Medical Center<\/h5>\n

\n\t\t\t\n\tStandardizing terminology and data linking between biorepository, clinical and assay data for downstream analysis\n\t\t\t<\/a>\n\t<\/h3>\n\t

Marybeth Joshi has spent more than 20 years directing complex, multi-faceted, multi-institutional, and multi-disciplinary clinical, translational, and basic science, as well as clinical outcomes research projects in oncology.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33149″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/merja-perala\/merja_perala_biotech_pharma_summit_photo_auria_bank_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Merja_perala_BioTech_Pharma_Summit_Photo_Auria_Bank_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMerja Per\u00e4l\u00e4\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Project Manager at Auria Biobank<\/h5>\n

\n\t\t\t\n\tHospital Biobank Samples and Data for Real-World Evidence Studies\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Merja Per\u00e4l\u00e4 joined Auria Biobank at 2017. Auria is Finland\u2019s first biobank established in connection with Turku University Hospital and the University of Turku. Merja works as project manager taking care of biobank sample and data request and granting process for research both in academia and industry.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33055″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/michael-roehrl\/michael_roehrl_memorial_sloan_cancer_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Michael_Roehrl_Memorial_Sloan_Cancer_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMichael Roehrl\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director, Precision Pathology Biobanking Center at Memorial Sloan Kettering Cancer Center<\/h5>\n

\n\t\t\t\n\tBig Data and AI in Science-Driven Biobanking: The Next Frontier\n\t\t\t<\/a>\n\t<\/h3>\n\t

Michael Roehrl M.D., Ph.D., is Director of the Precision Pathology Biobanking Center at Memorial Sloan Kettering Cancer Center, New York, USA. He is dually board-certified in Pathology and Laboratory Medicine. He holds an MD from the Technical University of Munich, a Ph.D. in Biological Chemistry from Harvard University, and trained clinically at Massachusetts General Hospital in Boston.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33026″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/pasquale-de-blasio\/pasquale_de_blasio_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pasquale_De_Blasio_BioTech_Pharma_Summit_Profile_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tPasquale De Blasio\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Executive Vice President at ISENET Biobanking<\/h5>\n

\n\t\t\t\n\tStem Cells (iPS)\n\t\t\t<\/a>\n\t<\/h3>\n\t

Pasquale De Blasio the Executive Vice President of ISENET Biobank. He is also the founder president of ESBB (European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) and Founder of Integrated Systems Engineering srl leader in Tissue Microarray Platforms. Pasquale graduated in Electrical Engineering from Villanova University (PA, USA, 1976), acquired his Master in Engineering Management from Drexel University (PA, USA, 1980) and a Master in Business Administration from Bocconi University (Milano, Italy, 1986).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33086″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/peadar-mac-gabhann\/peadar_mac_gabhann_biostor_ireland_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Peadar_Mac_Gabhann_Biostor_Ireland_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tPeadar Mac Gabhann\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Managing Director at Biost\u00f3r Ireland<\/h5>\n

\n\t\t\t\n\tEstablishment of the VISICORT Foundation Biobank for Eye Disease\n\t\t\t<\/a>\n\t<\/h3>\n\t

Peadar Mac Gabhann graduated from the National University of Ireland, University College Dublin with a M.Sc. in Industrial Microbiology. He carried out post graduate research at the Netherlands Cancer Institute (NKI) Amsterdam, Biogen at ETH Zurich and the Faculty of Medicine at Kyoto University Japan.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rita_Lawlor_Biotech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rita_Lawlor_Biotech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rita_Lawlor_Biotech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rita_Lawlor_Biotech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rita_Lawlor_Biotech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rita_Lawlor_Biotech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rita_Lawlor_Biotech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33039″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/rita-lawlor\/rita_lawlor_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rita_Lawlor_Biotech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Rita_Lawlor_Biotech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rita_Lawlor_Biotech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rita_Lawlor_Biotech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tRita Lawlor\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Biobank and Model Bank Director, Research Coordinator at ARC-NET : Centre for Applied Research on Cancer<\/h5>\n

\n\t\t\t\n\tEnsuring personal data protection in the EU under current and future regulatory framework\n\t\t\t<\/a>\n\t<\/h3>\n\t

Rita Lawlor is a Computer Science graduate of Trinity College Dublin with a doctorate in Oncological Pathology from the University of Verona where she is co-founder of the ARC-Net (www.arc-net.it) applied cancer research centre where is director of the ARC-Net biobank and coordinates research activities.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33080″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/robert-hewitt\/robert_hewitt_trans-hit_bio_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Robert_Hewitt_Trans-Hit_Bio_Biotech_Pharma_Summit_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tRobert Hewitt\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director, Biobank Consortia & Communications at Trans\u2013Hit Biomarkers, Inc.<\/h5>\n

\n\t\t\t\n\tAcademic biobanks and industry: overcoming obstacles to efficient collaboration and mutual benefit (presentation on behalf of Trans-Hit Biomarkers Inc)\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Robert Hewitt joined Trans-Hit Bio in November 2017. He is responsible for developing THB\u2019s existing international networks of biobanks and for enhancing interactions between industry and academic partners. Robert holds a medical degree from St Bartholomew\u2019s Hospital, London, UK (1983) and a PhD in tumour virology from the Institute of Virology, University of Glasgow, UK (1989).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33061″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/rohit-gupta\/rohit_gupta_stanford_biobank_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rohit_Gupta_Stanford_Biobank_BioTech_Pharma_Summit_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tRohit Gupta\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Executive Director, Stanford Biobank and Clinical Research Services (CTRU) at Stanford Medicine<\/h5>\n

\n\t\t\t\n\tNext-Generation Biobank in Academia\n\t\t\t<\/a>\n\t<\/h3>\n\t

Rohit Gupta began his research at Stanford Medicine in 2003 and now oversees the Stanford Biobank and leads the institute\u2019s largest, research focused, ambulatory care group (Spectrum\u2019s Clinical & Translational Research Unit). Notably, he\u2019s established biorepository and associated big data infrastructure for multiple large-scale biobanks, both locally and globally, while also designing innovative cost-recovery business models for clinical and lab related research services at the university.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33123″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/ronny-baber\/ronny_-baber_university_leipzig_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5.6","credit":"","camera":"Canon EOS 550D","caption":"","created_timestamp":"1472388915","copyright":"","focal_length":"80","iso":"2500","shutter_speed":"0.008","title":"","orientation":"1"}” data-image-title=”Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ronny_-Baber_University_Leipzig_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tRonny Baber\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Head of the LIFE-Biobank and Preanalytical Laboratory at University Hospital Leipzig<\/h5>\n

\n\t\t\t\n\tUsing the best practices for Biobanking\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Ronny Baber studied biochemistry and did his Ph.D. thesis in the Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics at the University Leipzig. Since 2010 he is the head of the LIFE-Biobank and the LIFE-Preanalytical laboratory (since 2014) in the Leipzig Research Center for Civilisation Diseases (LIFE).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33044″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/shona-kerr\/shona_kerr_university_edinburgh_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"4.5","credit":"","camera":"NIKON D850","caption":"","created_timestamp":"1532518231","copyright":"","focal_length":"185","iso":"200","shutter_speed":"0.008","title":"","orientation":"1"}” data-image-title=”Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shona_Kerr_University_Edinburgh_Biotech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tShona Kerr\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Project Manager at MRC Human Genetics Unit, Edinburgh<\/h5>\n

\n\t\t\t\n\tBalancing the local and the universal in maintaining ethical access to a genomics biobank\n\t\t\t<\/a>\n\t<\/h3>\n\t

Shona Kerr has more than 20 years of experience in the management of basic scientific research in academia. Her primary interest is in the genetics of quantitative traits using human population and family-based biobanks and linked electronic health record data.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33111″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/sigbjorn-gregusson\/sigbjorn_gregusson_biobank_as_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sigbjorn_Gregusson_BioBank_AS_Biotech_Pharma_Summit_2-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSigbj\u00f8rn Gregusson\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Executive manager at Biobank AS<\/h5>\n

\n\t\t\t\n\tFour essential factors for safe and rational production in an animal biobank\n\t\t\t<\/a>\n\t<\/h3>\n\t

Sigbj\u00f8rn Gregusson is the Executive Manager of BioBank AS(Ltd) in Hamar, Norway. Dr. Gregusson had several international missions in developing countries on Food safety issues (Baltic countries, Nepal, Uganda), and on quality control and assessments for microbiological laboratories (UNIDO, Pakistan).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33130″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/sofia-spyrou\/sofia_spyrou_nibsc_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sofia_Spyrou_NIBSC_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSofia Spyrou\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Production Manager at NIBSC<\/h5>\n

\n\t\t\t\n\tBanking of clinical grade human Pluripotent Stem Cells\n\t\t\t<\/a>\n\t<\/h3>\n\t

Sofia Spyrou has over six years of experience as a production manager. She joined the UK Stem Cell Bank at NIBSC in 2016 and currently manages the day to day banking operations. Her focus is to review, bank and distribute the MRC funded \u201cEUTCD-Grade\u201d human embryonic stem cell lines.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33136″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/svetlana-gramatiuk\/svetlana-gramatiuk-birka_biotech_pharma_summit_biobanking_2018_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"1516192323","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Svetlana-Gramatiuk-Birka_BioTech_Pharma_Summit_Biobanking_2018_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSvetlana Gramatiuk\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
President and Medical Director, Ukraine Association of Biobank<\/h5>\n

\n\t\t\t\n\tBiobank management model and plan sustainable in developing countries\n\t\t\t<\/a>\n\t<\/h3>\n\t

Svetlana Gramatiuk (MD PhD) serves as President of UAB (Ukraine Associated of Biobank) that she co-founded in 2017. She was also the Medical Director Research Biobank ASK-Health (2015-2016) and the Ukraine Editor of the journal Advanced research biobank and pathophysiology from 2017. Previously, Svetlana also established and\/or managed several biobanks in Ukraine.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33099″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/vincent-von-walcke-wulffen\/vincent_von_walcke_wulffen_biokryo_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5.6","credit":"","camera":"NIKON D200","caption":"","created_timestamp":"1289222807","copyright":"","focal_length":"85","iso":"100","shutter_speed":"0.005","title":"","orientation":"1"}” data-image-title=”Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Vincent_von_Walcke_Wulffen_Biokryo_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tVincent von Walcke-Wulffen\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CEO at BioKryo GmbH<\/h5>\n

\n\t\t\t\n\tGMP Biobanking in 2020\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. von Walcke-Wulffen, born in 1976 in D\u00fcsseldorf, went after school in Brussels and Saarbr\u00fccken for one year to the German Navy for his military service. In 1997 he started to study at the University of Hamburg Business Administration with a minor field of study in chemistry and graduated in 2003 with a master theses at a BASF plant by using evolutionary algorithm for productions planning in the chemical industry. From 1999 to 2003 he was supported by a scholarship of the Konrad Adenauer Foundation.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Our Speakers (A-Z) Alissa M. Resch Chief Scientific Officer at Coriell Institute for Medical Research The Evolving Role of Biobanks: Developing Metrics to Identify Future Needs As head of scientific operations at the Coriell Institute for Medicial Research, Dr. Alissa M. Resch oversees the scientific functions of the institute, including management of the contracts &…<\/p>\n","protected":false},"author":1,"featured_media":31716,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33015","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nBiobanking 2019 Speakers • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"On 14 & 15 February 2019, EPM Group will host the BioTech Pharma Summit: Biobanking 2019 in Porto, Portugal. This year event will bring together the world\u2019s leading experts in biorepositories, policy makers, and scientific actors\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biobanking 2019 Speakers • BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"On 14 & 15 February 2019, EPM Group will host the BioTech Pharma Summit: Biobanking 2019 in Porto, Portugal. This year event will bring together the world\u2019s leading experts in biorepositories, policy makers, and scientific actors\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-18T10:53:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Biobanking_Banner_New_Porto.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"993\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/\",\"name\":\"Biobanking 2019 Speakers • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Biobanking_Banner_New_Porto.png\",\"datePublished\":\"2020-08-11T11:02:10+00:00\",\"dateModified\":\"2021-03-18T10:53:48+00:00\",\"description\":\"On 14 & 15 February 2019, EPM Group will host the BioTech Pharma Summit: Biobanking 2019 in Porto, Portugal. This year event will bring together the world\u2019s leading experts in biorepositories, policy makers, and scientific actors\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Biobanking_Banner_New_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Biobanking_Banner_New_Porto.png\",\"width\":1920,\"height\":993},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biobanking 2019 Speakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biobanking 2019 Speakers • BioTech Pharma Summit","description":"On 14 & 15 February 2019, EPM Group will host the BioTech Pharma Summit: Biobanking 2019 in Porto, Portugal. This year event will bring together the world\u2019s leading experts in biorepositories, policy makers, and scientific actors","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/","og_locale":"en_US","og_type":"article","og_title":"Biobanking 2019 Speakers • BioTech Pharma Summit","og_description":"On 14 & 15 February 2019, EPM Group will host the BioTech Pharma Summit: Biobanking 2019 in Porto, Portugal. This year event will bring together the world\u2019s leading experts in biorepositories, policy makers, and scientific actors","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-18T10:53:48+00:00","og_image":[{"width":1920,"height":993,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Biobanking_Banner_New_Porto.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/","name":"Biobanking 2019 Speakers • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Biobanking_Banner_New_Porto.png","datePublished":"2020-08-11T11:02:10+00:00","dateModified":"2021-03-18T10:53:48+00:00","description":"On 14 & 15 February 2019, EPM Group will host the BioTech Pharma Summit: Biobanking 2019 in Porto, Portugal. This year event will bring together the world\u2019s leading experts in biorepositories, policy makers, and scientific actors","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Biobanking_Banner_New_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Biobanking_Banner_New_Porto.png","width":1920,"height":993},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Biobanking 2019 Speakers"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33015"}],"version-history":[{"count":4,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33015\/revisions"}],"predecessor-version":[{"id":35937,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33015\/revisions\/35937"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/31716"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}